

Targeted Therapies in Asthma [2017]: Bulletin #1

<https://marketpublishers.com/r/T87D706B2E5EN.html>

Date: April 2017

Pages: 0

Price: US\$ 1,045.00 (Single User License)

ID: T87D706B2E5EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the targeted asthma treatment market. Topics covered include; GlaxoSmithKline's (GSK) presentation of new data at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be indicative of a recalcitrant asthma phenotype), and new data for mepolizumab from the Phase III MUSCA trial is also discussed. Teva's presentation at AAAAI 2017 of new data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant clinical improvement in asthmatic symptoms with reslizumab (Cinqiar/Cinqaeor) therapy. Roche/Genentech's publication of 'real world' data from the PROSPERO study involving omalizumab (Xolair), with outcomes reflecting reductions in exacerbation frequency and hospitalisations achieved in earlier controlled clinical trials.

BUSINESS QUESTIONS:

In March 2017, GSK presented new data at AAAAI 2017 which demonstrates that mepolizumab's efficacy is not affected by the presence of nasal polyps, but what is the significance of this data and what impact will it have on prescribing practice?

At AAAAI 2017, Teva presented data showing that patients with inadequately controlled asthma and aspirin sensitivity received significant improvement in symptoms with reslizumab therapy, but what is the prevalence of aspirin sensitivity and how will the data influence prescribing practice?

GSK and Teva have both published results from meta-analysis of Phase III studies that prove efficacy of mepolizumab and reslizumab respectively in a

subgroup of patients acknowledged to be recalcitrant to standard therapies, but which of these products will be most appealing to prescribers and patients?

In March 2017, GSK published new data from the Phase III MUSCA study demonstrating mepolizumab's efficacy in the treatment of severe asthma with an eosinophilic phenotype; primary outcomes, for the first time, included patient reported quality of life improvements. What is the impact of this data and can mepolizumab usage be expected to increase?

Roche/Genentech published new data from the PROSPERO study that confirms omalizumab's efficacy in treating allergic asthma in a 'real world' setting. How is this data likely to be received amongst prescribers and will omalizumab usage increase?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

I would like to order

Product name: Targeted Therapies in Asthma [2017]: Bulletin #1

Product link: <https://marketpublishers.com/r/T87D706B2E5EN.html>

Price: US\$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T87D706B2E5EN.html>